CAVE CREEK, AZ–(Marketwired – Dec 15, 2015) –
Endexx Corporation (OTC PINK: EDXC), a provider of innovative medical marijuana management and technology solutions, announced today the start of a new small scale case study of plantar fasciitis patients utilizing CBD Unlimited’s certified, Colorado grown hemp oil blends, rich in both cannabidiol and other key phyto-nutrients.
The study, supervised by Dr. Daniel Kiddy, DPM, is comprised of ten volunteer patients taking CBD-rich hemp oil sublingually for up to forty-five days. Two million patients are treated for Plantar Fasciitis in the US every year according to the American Academy of Orthopedic Surgeons. The condition is caused by the inflammation of the plantar fascia. Cannabidiol has been shown in multiple clinical studies to have powerful anti-inflammatory properties.
Dr. Kiddy, a foot and ankle specialist who treats plantar fasciitis patients on a daily basis, stated: “Many cases of plantar fasciitis occur due to nerve inflammation of the medial calcaneal branch coming off the posterior tibial nerve or from inflammation to the first branch off the lateral plantar nerve known as Baxter’s nerve. The goal of the study is to record changes in pain levels for patients diagnosed with plantar fasciitis through the administration of CBD-rich oil provided by CBD Unlimited.”
The diabetic neuropathy study started a year ago in Missouri has been concluded. Almost all of the 13 patients who participated in the trial experienced improvement. Improvement was described as being able to sleep, not wake up with pain, feeling more rested and increased energy. One of the patients had chronic migraine headaches, for which she was taking eighteen Imitrex per month in addition to Gabapentin and Zonisamize. The patient is now down to two Imitrex per month and is off her other two medications completely. Patients are now using CBD-rich hemp oil from CBD Unlimited instead of prescription medications, per their doctor’s advice, with decreased pain and a better quality of life.
Todd Davis, CEO of Endexx, stated, “Through testimony of our clients and feedback from patients voluntarily participating in these studies, we are finding that secondary pain and inflammation related symptoms are improving through the use of our Phyto-Cannabinoid enriched blends. Testimonies come in weekly about the benefits provided by our products. We will continue to support baseline case studies that build a more complete understanding of the benefits derived from organic hemp extracts.”
About Endexx Corp.:
Endexx provides innovative medical marijuana management and technology solutions. Endexx, with its collaborative partners and consultants, develops and distributes two consumable product lines derived from industrial hemp, which is organic and naturally rich in phytocannabinoids. The company has two technology products and services that launched in 2014 — the M3hub and the Autospense™. Both products provide essential solutions to promote regulatory compliance and full accountability through “seed to sale” inventory management and tracking. Based on principles developed by the pharmacological industry, the m3hub platform is the first standardized software solution for tracking pharmaceutical grade marijuana that maintains compliance with federal, state and local regulations. It is intended to provide a smooth transition to an eventual federal mandates. The Autospense™ is a high-tech marijuana inventory control and dispensing device that provides up-to-the-minute accounting details and ensures both product and patient security. By automating the dispensing process, Autospense™ increases productivity and reduces costs for marijuana retailer, while enhancing their service quality by reducing transaction time for customers.
Disclaimer/ Disclosure: The Investors News Magazine is a third party publisher of news and research as well as creates original content as a news source. Original content created by Investors News Magazine is protected by copyright laws other than syndication rights. Our site does not make recommendations for purchases or sale of stocks or products. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. All investment involves risk and possible loss of investment. This site may be compensated by featured companies for news submissions and content marketing. Contact each company directly for press release questions. Disclosure is posted on each release if required but otherwise the news was not compensated for and is published for the sole interest of our readers.